Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 27, 2015 9:23 PM ET

Healthcare Providers and Services

Company Overview of University Health Network

Company Overview

University Health Network provides patient care, education, and research services in Canada. The company operates four hospital sites, including Princess Margaret Hospital, Toronto General Hospital, Toronto Western Hospital, and Toronto Rehabilitation Institute. Its Princess Margaret Hospital offers diagnostic, treatment, and follow-up care services in medical, surgical, and radiation oncology areas with 12 site groups and 26 specialty clinics. The company’s Toronto General Hospital provides services in the areas of cardiac care, organ transplants, and the treatment of complex patient needs. Its Toronto Western Hospital offers services in the areas of neuroscience, musculoskeletal health, an...

190 Elizabeth Street

Toronto, ON M5G 2C4




Key Executives for University Health Network

Chief Executive Officer and President
Medical Director of the Medicine and Community Health Program
Director of Technology Development and Commercialization
Compensation as of Fiscal Year 2014.

University Health Network Key Developments

Generex Biotechnology Corp. Collaborates with University Health Network for Buccal Insulin Project

Generex Biotechnology Corporation announced that it has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the Company's buccal insulin refinement project. The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. This research will ensure the product is more attractive to patients and prospective commercialization partners.

University Health Network Appoints Dr. Peter Pisters as President & Chief Executive Officer

University Health Network announced that Dr. Peter Pisters, currently Vice President of The University of Texas MD Anderson Cancer Center's Regional Care System, will serve as UHN's next President & CEO. Dr. Pisters has held a number of clinical, administrative and leadership positions at MD Anderson from 1994 to the present with his most recent executive responsibilities being the management of 6 MD Anderson centers for care across metropolitan Houston. Prior to his current role he was Medical Director of the regional cancer centers, Clinical Consultant for the Center for Global Oncology (now known as MD Anderson Cancer Network), Section Chief for Sarcoma Surgery with a specialty focus in the management of sarcoma and gastrointestinal cancer patients. Dr. Pisters takes on the role of President & CEO of UHN on January 1, 2015.

Sernova Corp. Agrees on Terms with the University Health Network of Toronto to Gain Access to Proprietary Stem Cell Technology for the Treatment of Diabetes

Sernova Corp. announced that it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes. Sernova and UHN have entered into a Term Sheet with an exclusive negotiation period which outlines the terms of the definitive license agreement for the granting of an exclusive license to Sernova covering all patent rights relating to the UHN stem cell technologies including for the treatment of diabetes. A product development program is also being designed to advance the technologies from preclinical proof-of-concept studies through to human testing on an expedited basis. Sernova believes the proprietary product - insulin producing stem cells, protected locally from immune system attack and placed within Sernova's prevascularized Cell Pouch(TM) - has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes, following successful preclinical and clinical testing. Such individuals could essentially be liberated from their current onerous regime of daily blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life while also reducing short term and longer term health care costs.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University Health Network, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at